Meschia M, Brincat M, Barbacini P, Maini M C, Marri R, Crosignani P G
2nd Department of Obstetrics and Gynecology, University of Milan, Italy.
Eur J Obstet Gynecol Reprod Biol. 1992 Oct 23;47(1):53-7. doi: 10.1016/0028-2243(92)90214-j.
A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonal replacement therapy and calcitonin not only prevented post-menopausal bone loss but resulted in a significant 10% gain in bone mass (P < 0.001).
总共104名绝经后女性被随机分配到不同的治疗方案中：(a)降钙素，(b)雌激素/孕激素（激素替代疗法）加降钙素，(c)雌激素/孕激素（激素替代疗法），(d)以及对照组。所有患者的腰椎骨量用双能光子吸收仪（Norland GD 153）进行评估。完成1年研究的73名患者显示，雌激素/孕激素（激素替代疗法）或降钙素均可预防绝经后骨质流失。此外，激素替代疗法与降钙素联合使用不仅预防了绝经后骨质流失，还使骨量显著增加了10%（P < 0.001）。
